Use of a hyperdried cross-linked amniotic membrane as initial therapy for corneal perforations
- PMID: 21331687
- DOI: 10.1007/s10384-010-0903-0
Use of a hyperdried cross-linked amniotic membrane as initial therapy for corneal perforations
Abstract
Purpose: To report the use of hyperdried cross-linked (HDCL) amniotic membrane (AM) patching with tissue adhesive as an initial therapy for corneal perforations.
Methods: Cryopreserved AM was cross-linked with 0.1% glutaraldehyde and then dried using far-infrared rays and microwaves (hyperdry method). Three eyes of three patients with corneal perforations of up to 3 mm in diameter were included in this study. They were treated with a single-layer patch of HDCL-AM applied with a tissue adhesive (2-octyl-cyanoacrylate). We also evaluated the resistance of HDCL-AM to collagenases during in vitro digestion testing.
Results: In all three cases, the corneal perforations were repaired within 28 days (range, 17-28 days). No recurrence occurred during the follow-up period (3-6 months). In the collagenase digestion testing, the HDCL-AM did not dissolve until 48 h, whereas the cryopreserved AM completely dissolved within 60 min.
Conclusions: Three cases of corneal perforations were successfully managed using HDCL-AM patching with tissue adhesive. The HDCL-AM was resistant to collagenases during in vitro digestion testing. The HDCL-AM was a useful substrate for corneal perforations. This simple surgical technique may be one of the initial therapeutic options for corneal perforations.
© Japanese Ophthalmological Society 2011.
Similar articles
-
A hyperdry amniotic membrane patch using a tissue adhesive for corneal perforations and bleb leaks.Am J Ophthalmol. 2009 Sep;148(3):383-9. doi: 10.1016/j.ajo.2009.03.030. Epub 2009 May 23. Am J Ophthalmol. 2009. PMID: 19464670
-
Cross-linking of human amniotic membrane by glutaraldehyde.Ophthalmic Res. 2004 Mar-Apr;36(2):71-7. doi: 10.1159/000076884. Ophthalmic Res. 2004. PMID: 15017101
-
Scleral Patch Graft Augmented Cyanoacrylate Tissue Adhesive for Treatment of Moderate-Sized Noninfectious Corneal Perforations (3.5-4.5 mm).Cornea. 2013 Oct;32(10):1326-30. doi: 10.1097/ICO.0b013e31829cb625. Cornea. 2013. PMID: 23974883
-
Management of corneal perforation.Surv Ophthalmol. 2011 Nov-Dec;56(6):522-38. doi: 10.1016/j.survophthal.2011.06.003. Surv Ophthalmol. 2011. PMID: 22117886 Review.
-
A brief review of techniques used to seal corneal perforation using cyanoacrylate tissue adhesive.Cont Lens Anterior Eye. 2013 Aug;36(4):156-8. doi: 10.1016/j.clae.2013.03.006. Epub 2013 Apr 24. Cont Lens Anterior Eye. 2013. PMID: 23623338 Review.
Cited by
-
Tumor Targeting by Conditioned Medium Derived From Human Amniotic Membrane: New Insight in Breast Cancer Therapy.Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036318. doi: 10.1177/15330338211036318. Technol Cancer Res Treat. 2021. PMID: 34402329 Free PMC article.
-
Modification of the Human Amniotic Membrane Using Different Cross-Linking Agents as a Promising Tool for Regenerative Medicine.Materials (Basel). 2023 Oct 17;16(20):6726. doi: 10.3390/ma16206726. Materials (Basel). 2023. PMID: 37895710 Free PMC article.
-
Comparison of the effects of preservation methods on structural, biological, and mechanical properties of the human amniotic membrane for medical applications.Cell Tissue Bank. 2024 Mar;25(1):305-323. doi: 10.1007/s10561-023-10114-z. Epub 2023 Oct 15. Cell Tissue Bank. 2024. PMID: 37840108 Review.
-
Augmented dried versus cryopreserved amniotic membrane as an ocular surface dressing.PLoS One. 2013 Oct 30;8(10):e78441. doi: 10.1371/journal.pone.0078441. eCollection 2013. PLoS One. 2013. PMID: 24205233 Free PMC article.
-
Significance of Crosslinking Approaches in the Development of Next Generation Hydrogels for Corneal Tissue Engineering.Pharmaceutics. 2021 Feb 28;13(3):319. doi: 10.3390/pharmaceutics13030319. Pharmaceutics. 2021. PMID: 33671011 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources